Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Accumulated Expenses: 2015-2016

  • Cartesian Therapeutics' Other Accumulated Expenses was N/A to $831,000 in Q2 2016 from the same period last year, while for Jun 2016 it was $831,000, marking a year-over-year change of. This contributed to the annual value of $223,000 for FY2015, which is N/A change from last year.
  • Per Cartesian Therapeutics' latest filing, its Other Accumulated Expenses stood at $831,000 for Q2 2016, which was up 272.65% from $223,000 recorded in Q4 2015.
  • Cartesian Therapeutics' 5-year Other Accumulated Expenses high stood at $831,000 for Q2 2016, and its period low was $223,000 during Q4 2015.
  • In the last 2 years, Cartesian Therapeutics' Other Accumulated Expenses had a median value of $527,000 in 2015 and averaged $527,000.